Analysts expect Insmed Incorporated (NASDAQ:INSM) to report earnings of ($0.87) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Insmed’s earnings, with estimates ranging from ($0.98) to ($0.56). Insmed posted earnings per share of ($1.00) during the same quarter last year, which indicates a positive year over year growth rate of 13%. The company is expected to announce its next earnings report on Thursday, August 1st.
On average, analysts expect that Insmed will report full year earnings of ($3.65) per share for the current year, with EPS estimates ranging from ($4.02) to ($2.94). For the next financial year, analysts expect that the firm will report earnings of ($2.57) per share, with EPS estimates ranging from ($3.05) to ($1.55). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Insmed.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.02). The company had revenue of $21.90 million during the quarter, compared to the consensus estimate of $19.61 million.
A number of equities analysts have recently weighed in on the company. ValuEngine lowered Insmed from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 28th. BidaskClub lowered Insmed from a “buy” rating to a “hold” rating in a research note on Wednesday, May 22nd. Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price objective (up previously from $43.00) on shares of Insmed in a research note on Tuesday, April 9th. Finally, Canaccord Genuity set a $44.00 target price on Insmed and gave the stock a “buy” rating in a research report on Friday, March 8th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $37.88.
NASDAQ:INSM traded up $0.79 during mid-day trading on Thursday, hitting $25.30. 835,152 shares of the company traded hands, compared to its average volume of 982,644. The company has a fifty day moving average of $25.97. Insmed has a one year low of $11.31 and a one year high of $33.13. The company has a debt-to-equity ratio of 2.48, a quick ratio of 4.69 and a current ratio of 4.82. The company has a market cap of $1.99 billion, a price-to-earnings ratio of -6.07 and a beta of 3.04.
In related news, Director Donald J. Hayden, Jr. sold 6,286 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $32.99, for a total value of $207,375.14. Following the transaction, the director now owns 68,483 shares of the company’s stock, valued at $2,259,254.17. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 400,000 shares of the stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $26.00, for a total value of $10,400,000.00. Following the sale, the chief executive officer now directly owns 480,672 shares in the company, valued at approximately $12,497,472. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 418,286 shares of company stock worth $10,886,255. Insiders own 4.95% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in INSM. FMR LLC raised its stake in shares of Insmed by 0.6% during the 1st quarter. FMR LLC now owns 11,630,784 shares of the biopharmaceutical company’s stock valued at $338,107,000 after buying an additional 67,250 shares during the last quarter. Foresite Capital Management IV LLC raised its stake in shares of Insmed by 9.8% during the 4th quarter. Foresite Capital Management IV LLC now owns 1,977,236 shares of the biopharmaceutical company’s stock valued at $25,941,000 after buying an additional 176,649 shares during the last quarter. Vivo Capital LLC purchased a new position in shares of Insmed during the 1st quarter valued at about $34,020,000. Emerald Advisers LLC raised its stake in shares of Insmed by 52.8% during the 1st quarter. Emerald Advisers LLC now owns 921,527 shares of the biopharmaceutical company’s stock valued at $26,789,000 after buying an additional 318,482 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Insmed by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 866,489 shares of the biopharmaceutical company’s stock valued at $11,368,000 after buying an additional 55,026 shares during the last quarter.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Story: Why Net Income is Important to Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.